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Abstract
Background: Dyspnea, or shortness of breath, is a common symptom in patients with advanced
cancer. Pharmacologic management is of proven benefit, but it does not help all patients.
Preliminary data suggest that acupuncture can relieve dyspnea in a variety of populations, including
cancer patients. We conducted a pilot study (ISRCTN89462491) preparatory to a fully powered
randomized, placebo-controlled trial to determine whether acupuncture reduces dyspnea in
patients with lung or breast cancer.
Methods: The study sample was comprised of forty-seven patients with lung or breast cancer
presenting with dyspnea. Patients receiving symptomatic treatments were not excluded as long as
no changes in management were planned during the trial. Patients were randomized to receive a
single session of true or placebo acupuncture in addition to their existing dyspnea treatments.
Semi-permanent acupuncture "studs" were then inserted: patients applied pressure to these studs
twice a day to provide ongoing stimulation to acupuncture points. The subjective sensation of
dyspnea was assessed with a 0 – 10 numerical rating scale immediately before and after acupuncture
treatment and daily for a week thereafter.
Results: All but two of 47 randomized patients provided follow-up data. Dyspnea scores were
slightly higher for patients receiving true versus placebo acupuncture, for both the period
immediately following acupuncture treatment and for the daily one week follow-up (differences
between means of 0.34, 95% C.I. -0.33, 1.02 and 0.56, 95% C.I. -0.39, 1.51). The 95% confidence
interval excludes the prespecified minimum clinically significant difference of a 20% greater
improvement in dyspnea for patients receiving acupuncture.
Conclusion: The acupuncture technique used in this trial is unlikely to have effects on dyspnea
importantly larger than placebo for patients with advanced cancer.
Background
Dyspnea, or shortness of breath, is defined as the subjec-
tive experience of difficulty breathing. It is a common
symptom in cancer patients, particularly those with
advanced cancer. For example, in a general survey of 100
outpatients and 140 inpatients at a Veterans' Affairs Med-
ical Center, at least some dyspnea was reported by 50% of
patients [1]. Studies of patients with advanced disease
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find that 50 –70% experience significant dyspnea[2,3].
Although dyspnea is most commonly associated with
lung cancer[3], high rates also occur in patients with
breast cancer with pulmonary metastases[4].
Dyspnea in cancer patients has numerous causes. It may
result from complications of the cancer itself, such as pul-
monary embolism, pleural effusion, anemia, and endo-
bronchial obstruction or from conditions associated with
a risk factor such as chronic obstructive pulmonary dis-
ease (COPD) in smokers. It may also result from disorders
not directly attributable to the lungs, such as congestive
heart failure or anemia. Treatment of these patients is typ-
ically guided by the identification of a specific underlying
abnormality. Pleural effusions, for instance, are treated by
thoracentesis, COPD is treated by bronchodilators and/or
steroids, and anemia is treated by transfusion.
Unfortunately, a specific lung or cardiac pathology is not
identifiable in approximately one-quarter of patients[2].
Moreover, dyspnea may result from causes in which defin-
itive treatment has been unsuccessful or not practical. A
number of interventions have been attempted for such
patients, who often have advanced cancer within the lung
parenchyma or endobronchial disease refractory to exter-
nal beam radiation. Several randomized trials have shown
that both opioids and supplemental oxygen can alleviate
the subjective sensation of dyspnea among patients with
advanced cancer.
For example, in a randomized, double-blind, crossover
trial, dyspnea sensation fell by 25 mm on a 100 mm visual
analog scale after morphine, with little change on placebo
(p < 0.01 for difference between groups)[5]. Using a sim-
ilar randomized, crossover design, Bruera et al. reported
highly significant differences between periods when
patients received oxygen as compared to periods when
unsupplemented air was administered [6]. However, such
measures are not effective in all patients, and the problem
of dyspnea in the cancer patient is often frustratingly dif-
ficult to treat. A multinational study of end-of life-care
found that dyspnea required sedation in 25 to 50% of
patients during the last week of life[7]. It is for these diffi-
cult to treat cancer patients that additional therapeutic
options are needed.
A number of randomized controlled trials have examined
acupuncture for shortness of breath in patients without
cancer. For example, a randomized, double-blind, pla-
cebo-controlled trial of acupuncture for methacholine-
induced asthma reported significant differences in favor
of acupuncture[8]. A similar study involved a standard-
ized running test to induce bronchorestriction in asthmat-
ics. Exercise-induced reductions in lung function were
significantly lower in real compared to placebo acupunc-
ture[9]. A trial in COPD reported significant differences
between groups for subjective breathlessness. Thirty-one
patients were randomized to self-administer finger pres-
sure ("acupressure") at true or sham acupuncture points
on a double-blind, crossover basis. Acupressure led to
approximately a one-third reduction of scores on a VAS of
dyspnea compared to about a 20% improvement in pla-
cebo controls[10].
Only one trial has been reported in cancer. Although
uncontrolled, the results are provocative. Thirty cancer
patients in palliative care received a single session of acu-
puncture. The mean visual analog score for breathlessness
before acupuncture treatment was 42; this fell to 24
immediately following 10 minutes of needle insertion, an
improvement that was maintained at six hour follow-up.
Symptom scores returned to baseline 24 hours later[11].
Given these data, we believed it would be worthwhile to
investigate whether cancer-related dyspnea can be relieved
by acupuncture. Acupuncture is a complementary ther-
apy, and therefore was administered as a supplement to
use of pharmacologics or oxygen for dyspnea. Placebo
control was employed because our endpoint was subjec-
tive and because acupuncture had not previously been
found superior to placebo for cancer-related dyspnea. Our
overall objective was to determine whether true acupunc-
ture was more effective than placebo for alleviating dysp-
nea in patients with advanced lung or breast cancer. Here
we report the results of a pilot study that aimed to refine
the methodology for an anticipated definitive trial.
Methods
Recruitment for the trial took place between July 2001
and March 2004 among patients under treatment for
advanced lung or breast cancer at Memorial Sloan-Ketter-
ing Cancer Center (MSKCC). Patients age 18 or above
with subjective complaint of shortness of breath and scor-
ing grade two or higher on the American Thoracic Society
Breathlessness Scale were eligible. Patients must have pur-
sued a trial of steroid medication for dyspnea, if indicated,
for at least 48 hours. Patients were excluded if any of the
following applied: shortness of breath predated cancer
diagnosis (e.g. asthma); recent onset of symptoms (< 7
days); anemia (defined as hemoglobin < 8 gm/dl); recent
acupuncture; contraindications to acupuncture such as
heart valve dysfunction or pancytopenia; planned initia-
tion or change in oncologic therapy or symptomatic man-
agement of breathlessness (continuation of any existing
management was allowed), or likelihood of patient death
during the course of anticipated participation in the trial.
Patients were also excluded if the primary cause of dysp-
nea was thought to be congestive heart failure, sarcoid dis-
ease, hypersensitivity pneumonitis, cryptogenic
organizing pneumonitis, pneumothorax, chest wallBMC Palliative Care 2005, 4:5 http://www.biomedcentral.com/1472-684X/4/5
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deformity, obesity, neuromuscular disorders, pulmonary
vascular disease, hepatomegaly or phrenic nerve paralysis
syndrome. If the primary cause of dyspnea was ascites,
effusion, pneumonia, large airway obstruction, superior
vena cava syndrome or pulmonary embolism, patients
were eligible only if they remained short of breath despite
conventional therapy administered by their primary
oncologist, or if they had refused such therapy.
Eligible consenting patients were randomized by tele-
phone using the MSKCC clinical research database. Rand-
omization used randomly permuted blocks with the
cancer diagnosis (lung/breast) and breathless at rest (yes/
no) as strata. The use of independent telephone registra-
tion and randomization ensured concealment of treat-
ment allocation. Patients, researchers and others involved
in patient care were blind to study group; only the acu-
puncturists and a researcher not associated with the study
were aware of which patients received true and which pla-
cebo treatment.
Treatment consisted of two phases, acupuncture and acu-
pressure. Patients received either true acupuncture fol-
lowed by true acupressure, or placebo acupuncture
followed by placebo acupressure. The first "acupuncture
phase" consisted of a single treatment in which real or pla-
cebo needles were applied for 15 minutes at true or sham
points, respectively. In the true acupuncture group, the
needles used were stainless steel AsiaMed No.16 30 mm ×
0.30 mm inserted to the traditional Chinese depth of 0.5
cm – 1.5 cm. Auricular points were needled with stainless
steel Seirin D type No. 1 15 mm × 0.16 mm. As is com-
mon in traditional acupuncture, practitioners attempted
to elicit de qi to help determine exact point location, but
there was no manipulation of needles after placement.
Placebo needles consist of a blunted needle that moves up
inside its handle instead of into the skin. This technique
has previously been demonstrated to be indistinguishable
from true acupuncture[12]. Patients were told that in pla-
cebo acupuncture "the needles are placed so that they do
not stimulate the correct acupuncture points. However,
they do not look or feel any different from real needles."
Immediately after insertion of the needles, patients were
asked to assess the credibility of their treatment using a
previously published scale[13,14].
The point prescription is described in Table 1. True points
were chosen on the basis of the prior case series[11] and
points traditionally used for breathlessness[15]; sham
points were chosen in body areas away from true acu-
puncture points. The point prescription was modified
slightly during the trial (details available on request), pri-
marily to improve patient comfort. Patient outcome was
not affected by the prescription used (see Results). Imme-
diately after needle insertion, acupuncturists completed
an audit sheet verifying the acupuncture points used.
These records were routinely reviewed, and acupuncturists
were found to have followed the acupuncture point
prescription.
One hour after removal of needles, patients started the
second "acupressure phase." Stainless steel AcuMedic acu-
Table 1: Location of acupuncture points.
Point Laterality Anatomical location
Ren6 Unilateral On the midline of the lower abdomen, 1.5 cun* inferior to the umbilicus and 3.5 cun* superior to the 
pubic symphysis
LU1 Bilateral On the lateral aspect of the chest, in the first intercostal space, 6 cun* lateral to the midline,
LU7 Bilateral On the radial aspect of the forearm, in the cleft between the tendons of brachioradialis and abductor 
pollicis longus
ST36 Bilateral Below the knee, 3 cun* inferior to Dubi ST35, one finger breadth lateral to the anterior crest of the tibia.
KI6 Bilateral 1 cun* below the prominence of the medial malleolus, in the groove formed by two ligamentous bundles.
Auricular lung point Bilateral Medial and distal aspect of the tragus
Auricular kidney point Bilateral Medial and proximal aspect of the cymba conchae
Sternal points OR Ren17 Unilateral Two needles inserted in the top two inches of the sternum and inserted down to the periosteum. Weak 
or cachectic patients were treated at Ren17, which is found on the anterior midline, at the level with the 
fourth intercostal space, midway between the nipples
Sham sternal Unilateral Two points anywhere in the upper two inches of the sternum: placebo needle only
Sham1 Bilateral Posterior wrist, between radius & ulna, 1 cun* distal to radial & ulnar heads
Sham2 Bilateral Anterior arm, 3 cun* proximal and 3 cun* medial to the antecubital crease
Sham3 Bilateral Anterior arm, center of biceps brachii (midway between shoulder joint and antecubital crease)
Ear Sham Bilateral Adjacent to the "finger point", just below the helix of the auricle, at the apex
* a "cun" is a practical measurement used by acupuncturists equivalent to the greatest width of a patient's thumb at the distal phalanxBMC Palliative Care 2005, 4:5 http://www.biomedcentral.com/1472-684X/4/5
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Flow of participants through the trial Figure 1
Flow of participants through the trial.
Allocated to acupuncture (n=25) 
 Received  acupuncture  (n=25) 
Provided follow-up data (n=25) 
Allocated to placebo (n=22) 
  Withdrew before learning allocation (n=1) 
  Received placebo (n=21) 
Provided follow-up data (n=20) 
Lost to follow up (n=1) 
Assessed for eligibility (n=220) 
Non-consent (n=97) 
Excluded (n=76) 
  Primary cause of dyspnea inappropriate (n=30) 
  Insufficient degree of dyspnea (n=18) 
 Anemia  (n=5) 
  Severe co-morbidity (n=6) 
 Acupuncture  contraindicated  (n=3)   
 Other  (n=14)
Randomized (n=47) BMC Palliative Care 2005, 4:5 http://www.biomedcentral.com/1472-684X/4/5
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pressure studs, sometimes described as "press," "semi-per-
manent" or "intradermal" acupuncture needles, were
used. These consist of a 2 mm × 0.28 mm acupuncture
needle attached to a metal ring embedded in surgical tape.
When the surgical tape is pressed on the skin, the needle
pierces the skin but its diameter is so fine that this sensa-
tion is neither painful nor even immediately obvious.
Acupressure studs have been used in a number of studies
with cancer patients[16,17]. Placebo studs have no nee-
dle: they were specially designed for research in end-of-life
populations by the author of the previous research on acu-
puncture for cancer related breathlessness[11].
To ensure retention of studs and guard against infection,
the studs were covered with Tegaderm following applica-
tion. Patients in the true acupuncture group were treated
with true studs at ST36; Sternal points or Ren17; Auricular
lung point and Auricular kidney point (see Table 1). Pla-
cebo patients received placebo studs at sham1, sham2 and
ear sham. We thought it possible that patients might
remove the studs before the end of the trial and that studs
with a visible needle might be more credible than those
without. Therefore, we also applied a placebo stud at
sham1 to the acupuncture group and a true stud at sham3
to the placebo group. We told patients that some studs
had small needles, others did not and that the choice
depended on where they were placed on the body.
Patients were also told that those in the placebo group
received treatment at points not thought to help
breathlessness.
Following application of the studs, patients were
instructed to apply pressure to the study by making small
circular movements with the fingers of the opposite hand,
2 – 3 cycles per second for 1 – 2 minutes per point. As is
typical for self-administered acupressure, patients were
encouraged to apply acupressure this way on waking, in
the early afternoon and during any exacerbation of symp-
toms. Initial instruction was provided verbally, at which
time patients were asked to confirm their understanding
by demonstrating the procedure. Patients also were given
easy-to-read written materials describing the acupressure
procedure.
Study acupuncturists are certified by the National Certifi-
cation Commission for Acupuncture and Oriental Medi-
cine (NCCAOM) and are licensed to practice acupuncture
in New York State. They have used acupuncture in clinical
practice for 3 – 25 years. All were employed at MSKCC
during the study and had considerable experience in treat-
ing cancer patients.
Outcome was measured in two ways. Every 15 minutes for
75 minutes immediately before acupuncture treatment
and one hour immediately after, patients rated their cur-
rent level of breathlessness on a 0 to 10 rating scale. They
then completed a dairy daily for seven days, recording
their average level of breathlessness through the day with
the same 0 to 10 scale, and recorded compliance with
acupressure.
The protocol was modified after 16 patients were accrued,
as we found that many in-patients had been excluded
because changes in management were likely in the subse-
quent seven days. We therefore modified the protocol so
that inpatients did not take part in the acupressure phase.
Moreover, many outpatients who complained of breath-
lessness in everyday life did not record significant breath-
lessness during the waiting period immediately before
acupuncture. Accordingly, we amended the protocol so
that outpatients completed the daily breathlessness diary
for a week at baseline. Only patients scoring a mean of
two or more were eligible. Out-patients who reported no
breathlessness at rest were not asked to report on symp-
toms in the period immediately before and after
acupuncture.
Preliminary power calculations on the basis of published
data[10,11] suggested that a sample of 120–150 patients
would be required to provide power to detect a clinically
significant difference between groups, defined as a 20%
lower follow-up dyspnea score in the acupuncture group
compared to placebo. For this pilot we sought a sample of
Table 2: Baseline characteristics of patients providing post 
randomization data. Values are number (percentage) or mean 
(standard deviation)
Acupuncture 
n = 25
Placebo 
n = 20
Female 15 (60%) 13 (65%)
Age 63.0 (12.8) 67.0 (11.4)
Diagnosis
breast 5 (20%) 4 (20%)
lung 20 (80%) 16 (80%)
Breathless at rest 9 (36%) 6 (30%)
Credibility score* 2.24 (0.46) 2.10 (0.59)
Steroid use:**
None 15 (60%) 9 (47%)
<40 mg prednisone equivalents 6 (24%) 8 (42%)
40+ mg prednisone equivalents 4 (16%) 2 (11%)
Diuretics** 3 (12%) 0 (0%)
Opiates** 5 (20%) 3 (16%)
Bronchodilators** 12 (48%) 7 (37%)
Fully compliant with acupressure+ 8 (80%)° 6 (75%)°°
* two missing observations in acupuncture group; three missing 
observations in placebo group
** one missing observation in placebo group
+ n = 10 acupuncture, n = 8 placebo
° one patient completely non-compliant, one patient 85% compliant
°° one patient 33% compliant, one patient 85% compliantBMC Palliative Care 2005, 4:5 http://www.biomedcentral.com/1472-684X/4/5
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40–50 patients. We felt that a sample of this size would
give us sufficient methodologic experience to conduct an
adequate fully powered study. Comparisons between
groups were by analysis of covariance (ANCOVA) with
baseline score and randomization strata as covariates.
Baseline score for the acupressure phase was the one week
baseline diary, if available, otherwise the immediate pre-
treatment breathlessness score was used. Patients were
analyzed in their randomized groups regardless of treat-
ment received. Prespecified sensitivity analyses were to
examine the effects of credibility on outcome and to assess
outcome for the acupuncture phase only in patients with
pre-treatment dyspnea scores greater than two. Statistical
analysis was conducted using Stata 8 (College Station,
Texas). No interim analyses were planned and the data
were not analyzed before study closure.
The study was approved by the institutional review board
at MSKCC in accordance with an assurance filed with and
approved by the Department of Health and Human Serv-
ices. Written informed consent was obtained from each
participant.
Results
Flow of participants through the trial is shown in figure 1.
Raw data are provided in Additional file 1. Table 2 shows
data on study completers. Groups are balanced for base-
line characteristics such as age, sex and diagnosis, and for
postrandomization characteristics such as credibility and
compliance. The similarity among credibility scores sug-
gests that blinding was maintained, a conclusion also sup-
ported by analysis of research assistant notes: of the 21
patients who commented on allocation during post-study
debriefing, 12 claimed to be unaware of allocation and
only four of the remaining nine made a correct guess as to
treatment received. Use of steroids, slightly more com-
mon in the placebo group, was not a strong predictor of
outcome and there was no interaction between steroid use
and group allocation. No patient changed use or dose of
diuretics, opiates, bronchodilators or steroids during
study participation.
Breathlessness scores are reported in Table 3. We give
results separately for dyspnea measured immediately after
acupuncture, and for dyspnea assessed by daily diary.
Some patients reporting dyspnea scores immediately after
acupuncture treatment had negligible pre-treatment dysp-
nea. Hence we also provide a sub-group analysis of the
immediate post-treatment scores, excluding patients scor-
ing a mean of 2 or below. For all analyses, patients receiv-
ing true acupuncture reported slightly higher scores at
follow-up, approximately equivalent to 10% of baseline.
Patients in both groups improved, but no important dif-
ferences between groups emerged. The upper bound of
the 95% confidence interval for the difference between
means excludes our prespecified minimum clinically sig-
nificant difference of a 20% greater improvement in dysp-
nea for patients receiving acupuncture. Credibility did not
predict breathlessness scores, either in the immediate
post-treatment period (p = 0.4) or during the one week of
diary recording (p = 0.9). Moreover, including credibility
in the model for treatment effect did not importantly
modify estimates.
We conducted exploratory analyses to determine whether
acupuncture prescription affected outcome. Outcome did
not differ by point prescription in either the subgroup
analysis (Table 4) or by including prescription and pre-
scription by group interaction in the ANCOVA model.
Table 3: Breathlessness scores. Baseline scores only given for patients providing relevant follow-up data. Values are mean (standard 
deviation)
Endpoint Group Baseline Follow-up p value for 
within group 
change
Difference 
between 
means+
95% C.I. p value for 
between group 
comparison
Immediately post-
treatment
Acupuncture n = 19: 4.09 (2.32) n = 19: 3.36 (2.21) 0.003 0.34 -0.33, 1.02 0.3
Placebo n = 14: 3.41 (2.79) n = 14: 2.42 (2.64) 0.003
Immediately post-
treatment (pre-
treatment score >2)
Acupuncture n = 15: 4.87 (1.92) n = 15: 3.99 (2.03) 0.003 0.45 -0.55, 1.46 0.4
Placebo n = 8: 5.28 (2.18) n = 8: 3.92 (2.50) 0.01
Mean of seven day 
breathlessness diary
Acupuncture n = 10*: 6.58 (1.71) n = 16*: 5.07 (2.12) 0.4 0.56** -0.39, 1.51 0.2
Placebo n = 7*: 5.99 (1.71) n = 14*: 3.77 (2.39) 0.07
+ Positive indicates worse score in acupuncture group.
* Some patients providing post-treatment diaries gave baseline data only for the immediately pre-treatment period
**n = 13 for placebo group: one patient had no baseline data.BMC Palliative Care 2005, 4:5 http://www.biomedcentral.com/1472-684X/4/5
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No adverse events were causally related to acupuncture
treatment.
Discussion
Although intended as a methodologic pilot, our results
are unexpectedly precise enough to warrant clinical rec-
ommendations. The confidence interval for the difference
between groups is sufficiently narrow for us to conclude
that, even in the best case scenario, the acupuncture tech-
nique tested is not importantly superior to placebo for
dyspnea in cancer patients. Based on our clinical judg-
ment of how much improvement we should expect to
make worthwhile the time and trouble associated with
acupuncture, we pre-specified a 20% difference between
groups as clinically meaningful. It is against this criterion
that we draw our conclusion of "no effect". Yet we can
exclude even smaller levels of benefit, such as 10%. We
find it unlikely that any patient or clinician would deem
acupuncture to be worthwhile for a benefit of one third of
a point on a 0 – 10 scale.
There are several possible limitations of our study. First,
protocol changes concerning intervention, eligibility and
evaluation, although common for a methodologic pilot,
are not ideal when drawing conclusions about the effec-
tiveness of a treatment. Nonetheless, we feel that these
protocol changes did not have an important influence on
our results. Changes in the methods of evaluation were
designed to reduce drop-out and improve the measure-
ment of baseline symptoms. These changes should
increase the precision of results. Amendments to
eligibility requirements were made to ensure that all
patients had non-zero symptom scores at baseline and
thus ensure that the trial included only those for whom
benefit was measurable. Modification of the intervention
itself is potentially more problematic. Most of the acu-
puncture point prescription changes were made to
increase patient comfort. For example, we initially used
the PC6 point on the wrist, but patients complained that
studs inserted there caused radiating pain, apparently due
to the proximity of PC6 to the median nerve. If our initial,
but not modified, prescription were of value, it would be
clinically irrelevant as an effective but intolerable treat-
ment has little clinical role. Moreover, we saw no evidence
that outcome was affected by the particular prescription
used.
Patients in this study received only a single acupuncture
treatment. This does not reflect traditional acupuncture
practice, and it is possible that repeated treatment might
have a cumulative effect. Our study design was based on
prior research that suggested immediate effects on dysp-
nea following a single session of acupuncture[8,11]
Delayed or cumulative effects are of questionable rele-
vance for symptomatic management in patients with late
stage cancer. Moreover, daily acupressure treatment had
no apparent effect.
It is possible that more encouraging findings may have
emerged had we used a different acupuncture technique,
such as modifying the point prescriptions for each patient.
Our study population reflected a typical spectrum of cases
requiring symptomatic management of dyspnea, and was
thus rather heterogeneous. Therefore, the possibility that
acupuncture might be effective for dyspnea in a sub-group
of patients with a particular pathology cannot be ruled
out. There is a dearth of systematically collected data to
inform decisions about study design with respect to either
the most effective acupuncture technique or the most
responsive patient group.
Our study provides some evidence of a placebo effect.
Symptom scores fell by approximately 20% immediately
after acupuncture in both groups (p = 0.003), a result
unlikely to be explained by regression to the mean or
other effects. It is plausible that such a result would have
been considered "positive" in a single-arm study, under-
scoring the importance of randomized trials for evaluat-
ing complementary therapies used to treat cancer-related
symptoms.
Accrual to the study was relatively slow, with only approx-
imately 15 patients entering per year. This is due in part to
the fact that MSKCC does not provide hospice services,
which limits the number of end of life patients, when dys-
pnea is most prevalent. Accrual was also limited by patient
refusal, as nearly half of patients approached declined par-
ticipation. Patients with advanced cancer admitted to
Table 4: Effect of acupuncture point prescription on outcome.
Endpoint Point prescription n Difference between groups+ 95% C.I.
Immediately post-treatment Initial 15 -0.23 -1.23, 0.77
Modified 18 0.87 -0.19, 1.94
Daily Breathlessness diary Initial 12 0.63 -0.54, 1.79
Modified 17 0.43 -0.92, 1.77
+ Positive indicates worse score in acupuncture groupPublish with BioMed Central    and   every 
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MSKCC generally have severe medical problems. Accord-
ingly, they often feel overwhelmed, and a clinical trial,
regardless of its perceived benefits and risks, is perceived
as an additional burden. Patients commonly noted in
response to the invitation to participate that "I just can't
face dealing with this right now".
Conclusion
We conclude that the acupuncture technique used in this
trial is unlikely to have effects importantly larger than pla-
cebo for dyspnea in patients with advanced cancer.
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